Literature DB >> 31501924

Subcortical TDP-43 pathology patterns validate cortical FTLD-TDP subtypes and demonstrate unique aspects of C9orf72 mutation cases.

Ian R Mackenzie1, Manuela Neumann2.   

Abstract

Frontotemporal lobar degeneration with TDP-43 immunoreactive (TDP-ir) inclusions (FTLD-TDP) is sub-classified based on the pattern of neocortical pathology, with each subtype showing clinical and genetic correlations. Recent studies indicate that accurate subtyping of cases may be important to help identify genetic risk factors and develop biomarkers. Although most FTLD-TDP cases are easily classified, some do not match well to one of the existing subtypes. In particular, cases with the C9orf72 repeat expansion (C9+) have been reported to show FTLD-TDP type A, type B or a combination of A and B pathology (A + B). In our series of FTLD-TDP cases, we found that those lacking the C9orf72 mutation (non-C9) were all readily classified as type A (n = 29), B (n = 16) or C (n = 18), using current criteria and standard observational methods. This classification was validated using non-biased hierarchical cluster analysis (HCA) of neocortical pathology data. In contrast, only 14/28 (50%) of the C9+ cases were classified as either pure type A or pure type B, with the remainder showing A + B features. HCA confirmed separation of the C9+ cases into three groups. We then investigated whether patterns of subcortical TDP-ir pathology helped to classify the difficult cases. For the non-C9 cases, each subtype showed a consistent pattern of subcortical involvement with significant differences among the groups. The most distinguishing features included white matter threads, neuronal intranuclear inclusions in hippocampus and striatum, and delicate threads in CA1 in type A; glial cytoplasmic inclusions in white matter and neuronal cytoplasmic inclusions (NCI) in lower motor neurons in type B; compact NCI in striatum in type C. HCA of the C9+ cases based on subcortical features increased the number that clustered with the non-C9 type A (46%) or non-C9 type B (36%); however, there remained a C9+ group with A + B features (18%). These findings suggest that most FTLD-TDP cases can be classified using existing criteria and that each group also shows characteristic subcortical TDP-ir pathology. However, C9+ cases may be unique in the degree to which their pathology overlaps between FTLD-TDP types A and B.

Entities:  

Keywords:  C9orf72; FTLD-TDP; Frontotemporal dementia; Frontotemporal lobar degeneration; TDP-43

Year:  2019        PMID: 31501924     DOI: 10.1007/s00401-019-02070-4

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  14 in total

Review 1.  The imaging signature of C9orf72 hexanucleotide repeat expansions: implications for clinical trials and therapy development.

Authors:  Stacey Li Hi Shing; Mary Clare McKenna; We Fong Siah; Rangariroyashe H Chipika; Orla Hardiman; Peter Bede
Journal:  Brain Imaging Behav       Date:  2021-01-05       Impact factor: 3.978

2.  Cortical and subcortical pathological burden and neuronal loss in an autopsy series of FTLD-TDP-type C.

Authors:  Allegra Kawles; Yasushi Nishihira; Alex Feldman; Nathan Gill; Grace Minogue; Rachel Keszycki; Christina Coventry; Callen Spencer; Jaclyn Lilek; Kaouther Ajroud; Giovanni Coppola; Rosa Rademakers; Emily Rogalski; Sandra Weintraub; Hui Zhang; Margaret E Flanagan; Eileen H Bigio; M-Marsel Mesulam; Changiz Geula; Qinwen Mao; Tamar Gefen
Journal:  Brain       Date:  2022-04-29       Impact factor: 13.501

3.  Frontotemporal Lobar Degeneration TDP-43-Immunoreactive Pathological Subtypes: Clinical and Mechanistic Significance.

Authors:  Manuela Neumann; Edward B Lee; Ian R Mackenzie
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Clinical Update on C9orf72: Frontotemporal Dementia, Amyotrophic Lateral Sclerosis, and Beyond.

Authors:  Dario Saracino; Isabelle Le Ber
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  Frontotemporal lobar degeneration proteinopathies have disparate microscopic patterns of white and grey matter pathology.

Authors:  Lucia A A Giannini; Claire Peterson; Daniel Ohm; Sharon X Xie; Corey T McMillan; Katya Raskovsky; Lauren Massimo; EunRah Suh; Vivianna M Van Deerlin; David A Wolk; John Q Trojanowski; Edward B Lee; Murray Grossman; David J Irwin
Journal:  Acta Neuropathol Commun       Date:  2021-02-23       Impact factor: 7.801

Review 6.  Frontotemporal lobar degeneration with TAR DNA-binding protein 43 (TDP-43): its journey of more than 100 years.

Authors:  Arenn F Carlos; Keith A Josephs
Journal:  J Neurol       Date:  2022-03-23       Impact factor: 6.682

7.  Neuronal RNA-binding protein dysfunction in multiple sclerosis cortex.

Authors:  Hannah E Salapa; Catherine Hutchinson; Bogdan F Popescu; Michael C Levin
Journal:  Ann Clin Transl Neurol       Date:  2020-07-01       Impact factor: 4.511

Review 8.  TDP-43 Pathology in Alzheimer's Disease.

Authors:  Axel Meneses; Shunsuke Koga; Justin O'Leary; Dennis W Dickson; Guojun Bu; Na Zhao
Journal:  Mol Neurodegener       Date:  2021-12-20       Impact factor: 14.195

9.  Downstream effects of polypathology on neurodegeneration of medial temporal lobe subregions.

Authors:  L E M Wisse; S Ravikumar; R Ittyerah; S Lim; J Lane; M L Bedard; L Xie; S R Das; T Schuck; M Grossman; E B Lee; M D Tisdall; K Prabhakaran; J A Detre; G Mizsei; J Q Trojanowski; E Artacho-Pérula; M M de Iñiguez de Onzono Martin; M M Arroyo-Jiménez; M Muñoz Lopez; F J Molina Romero; M P Marcos Rabal; S Cebada Sánchez; J C Delgado González; C de la Rosa Prieto; M Córcoles Parada; D A Wolk; D J Irwin; R Insausti; P A Yushkevich
Journal:  Acta Neuropathol Commun       Date:  2021-07-21       Impact factor: 7.801

10.  Antibody against TDP-43 phosphorylated at serine 375 suggests conformational differences of TDP-43 aggregates among FTLD-TDP subtypes.

Authors:  Manuela Neumann; Petra Frick; Francesca Paron; Jonas Kosten; Emanuele Buratti; Ian R Mackenzie
Journal:  Acta Neuropathol       Date:  2020-08-10       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.